163 related articles for article (PubMed ID: 33219385)
1. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model.
Tan SPF; Chan ECY; Chan JCY
ALTEX; 2021; 38(2):253-268. PubMed ID: 33219385
[TBL] [Abstract][Full Text] [Related]
2. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing.
Chan JCY; Tan SPF; Upton Z; Chan ECY
ALTEX; 2019; 36(4):597-612. PubMed ID: 31079160
[TBL] [Abstract][Full Text] [Related]
3. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.
Jamei M; Bajot F; Neuhoff S; Barter Z; Yang J; Rostami-Hodjegan A; Rowland-Yeo K
Clin Pharmacokinet; 2014 Jan; 53(1):73-87. PubMed ID: 23881596
[TBL] [Abstract][Full Text] [Related]
5. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
6. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat.
He J; Yu Y; Prasad B; Link J; Miyaoka RS; Chen X; Unadkat JD
Mol Pharm; 2014 Aug; 11(8):2745-54. PubMed ID: 24957348
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug.
Storelli F; Li CY; Sachar M; Kumar V; Heyward S; Sáfár Z; Kis E; Unadkat JD
Clin Pharmacol Ther; 2022 Sep; 112(3):593-604. PubMed ID: 35152400
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys.
Shen H; Su H; Liu T; Yao M; Mintier G; Li L; Fancher RM; Iyer R; Marathe P; Lai Y; Rodrigues AD
J Pharmacol Exp Ther; 2015 May; 353(2):380-91. PubMed ID: 25740896
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography Imaging of [
Billington S; Shoner S; Lee S; Clark-Snustad K; Pennington M; Lewis D; Muzi M; Rene S; Lee J; Nguyen TB; Kumar V; Ishida K; Chen L; Chu X; Lai Y; Salphati L; Hop CECA; Xiao G; Liao M; Unadkat JD
Clin Pharmacol Ther; 2019 Nov; 106(5):1056-1066. PubMed ID: 31102467
[TBL] [Abstract][Full Text] [Related]
12. Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics.
Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
Drug Metab Dispos; 2018 Jan; 46(1):66-74. PubMed ID: 29084782
[TBL] [Abstract][Full Text] [Related]
13. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
Posada MM; Bacon JA; Schneck KB; Tirona RG; Kim RB; Higgins JW; Pak YA; Hall SD; Hillgren KM
Drug Metab Dispos; 2015 Mar; 43(3):325-34. PubMed ID: 25504564
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz H; Hanke N; Taub ME; Wang T; Prasad B; Fernandez É; Stopfer P; Nock V; Lehr T
Pharm Res; 2020 Nov; 37(12):250. PubMed ID: 33237382
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment.
Gerner B; Scherf-Clavel O
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34067429
[TBL] [Abstract][Full Text] [Related]
17. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
18. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
Barton HA; Lai Y; Goosen TC; Jones HM; El-Kattan AF; Gosset JR; Lin J; Varma MV
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):459-72. PubMed ID: 23331046
[TBL] [Abstract][Full Text] [Related]
19. Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations.
Punt A; Bos P; Hakkert B; Louisse J
ALTEX; 2023; 40(2):237–247. PubMed ID: 35901496
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
Poirier A; Funk C; Scherrmann JM; Lavé T
Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
